Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram.

Yarravarapu N, Geffert L, Surratt CK, Cascio M, Lapinsky DJ.

Bioorg Med Chem Lett. 2018 Nov 15;28(21):3431-3435. doi: 10.1016/j.bmcl.2018.09.029. Epub 2018 Sep 22.

PMID:
30266542
2.

DARK Classics in Chemical Neuroscience: Ibogaine.

Wasko MJ, Witt-Enderby PA, Surratt CK.

ACS Chem Neurosci. 2018 Oct 17;9(10):2475-2483. doi: 10.1021/acschemneuro.8b00294. Epub 2018 Oct 9.

PMID:
30216039
3.

Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects.

Hong WC, Wasko MJ, Wilkinson DS, Hiranita T, Li L, Hayashi S, Snell DB, Madura JD, Surratt CK, Katz JL.

J Pharmacol Exp Ther. 2018 Sep;366(3):527-540. doi: 10.1124/jpet.118.250498. Epub 2018 Jun 26.

4.

Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.

Jean B, Surratt CK, Madura JD.

J Mol Graph Model. 2017 Sep;76:143-151. doi: 10.1016/j.jmgm.2017.07.003. Epub 2017 Jul 11.

5.

Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening.

Talbot JN, Geffert LM, Jorvig JE, Goldstein RI, Nielsen CL, Wolters NE, Amos ME, Munro CA, Dallman E, Mereu M, Tanda G, Katz JL, Indarte M, Madura JD, Choi H, Leak RK, Surratt CK.

Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:22-30. doi: 10.1016/j.pbb.2016.08.007. Epub 2016 Aug 26.

PMID:
27569602
6.

Editorial: In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other CNS-Active Drugs.

Surratt CK, Madura JD.

Front Pharmacol. 2016 Jan 8;6:302. doi: 10.3389/fphar.2015.00302. eCollection 2015. No abstract available.

7.

2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.

Hong WC, Kopajtic TA, Xu L, Lomenzo SA, Jean B, Madura JD, Surratt CK, Trudell ML, Katz JL.

J Pharmacol Exp Ther. 2016 Mar;356(3):624-34. doi: 10.1124/jpet.115.230722. Epub 2016 Jan 14.

8.

Teaching Pharmacology Graduate Students how to Write an NIH Grant Application.

Leak RK, O'Donnell LA, Surratt CK.

Am J Pharm Educ. 2015 Nov 25;79(9):138. doi: 10.5688/ajpe799138.

9.

A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets.

Wasko MJ, Pellegrene KA, Madura JD, Surratt CK.

Front Neurol. 2015 Sep 11;6:197. doi: 10.3389/fneur.2015.00197. eCollection 2015. Review.

10.

Discovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporter.

Nolan TL, Geffert LM, Kolber BJ, Madura JD, Surratt CK.

ACS Chem Neurosci. 2014 Sep 17;5(9):784-92. doi: 10.1021/cn500133b. Epub 2014 Jul 15. Review.

11.

New design strategies for antidepressant drugs.

Immadisetty K, Geffert LM, Surratt CK, Madura JD.

Expert Opin Drug Discov. 2013 Nov;8(11):1399-414. doi: 10.1517/17460441.2013.830102. Epub 2013 Aug 31. Review.

PMID:
23991860
12.

Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Lapinsky DJ, Yarravarapu N, Nolan TL, Surratt CK, Lever JR, Tomlinson M, Vaughan RA, Deutsch HM.

ACS Med Chem Lett. 2012 May 10;3(5):378-382. Epub 2012 Mar 11.

13.

Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.

Manepalli S, Surratt CK, Madura JD, Nolan TL.

AAPS J. 2012 Dec;14(4):820-31. doi: 10.1208/s12248-012-9391-0. Epub 2012 Aug 24. Review.

14.

(±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).

Lapinsky DJ, Aggarwal S, Nolan TL, Surratt CK, Lever JR, Acharya R, Vaughan RA, Pandhare A, Blanton MP.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):523-6. doi: 10.1016/j.bmcl.2011.10.086. Epub 2011 Nov 4.

15.

Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization.

Nolan TL, Lapinsky DJ, Talbot JN, Indarte M, Liu Y, Manepalli S, Geffert LM, Amos ME, Taylor PN, Madura JD, Surratt CK.

ACS Chem Neurosci. 2011 Jun 8;2(9):544-552.

16.

Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Manepalli S, Geffert LM, Surratt CK, Madura JD.

J Chem Inf Model. 2011 Sep 26;51(9):2417-26. doi: 10.1021/ci200280m. Epub 2011 Sep 2.

17.

Research funding expectations as a function of faculty teaching/administrative workload.

Surratt CK, Kamal KM, Wildfong PL.

Res Social Adm Pharm. 2011 Jun;7(2):192-201. doi: 10.1016/j.sapharm.2010.04.006. Epub 2010 Jul 23.

PMID:
21272546
18.

Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Lapinsky DJ, Velagaleti R, Yarravarapu N, Liu Y, Huang Y, Surratt CK, Lever JR, Foster JD, Acharya R, Vaughan RA, Deutsch HM.

Bioorg Med Chem. 2011 Jan 1;19(1):504-12. doi: 10.1016/j.bmc.2010.11.002. Epub 2010 Nov 4.

19.

Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.

Kopajtic TA, Liu Y, Surratt CK, Donovan DM, Newman AH, Katz JL.

J Pharmacol Exp Ther. 2010 Dec;335(3):703-14. doi: 10.1124/jpet.110.171629. Epub 2010 Sep 20.

20.

Succession planning in US pharmacy schools.

Van Amburgh J, Surratt CK, Green JS, Gallucci RM, Colbert J, Zatopek SL, Blouin RA.

Am J Pharm Educ. 2010 Jun 15;74(5). pii: 86.

21.
22.

Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer.

Gedeon PC, Indarte M, Surratt CK, Madura JD.

Proteins. 2010 Mar;78(4):797-811. doi: 10.1002/prot.22601.

PMID:
19899168
23.

A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

Lapinsky DJ, Aggarwal S, Huang Y, Surratt CK, Lever JR, Foster JD, Vaughan RA.

Bioorg Med Chem. 2009 Jun 1;17(11):3770-4. doi: 10.1016/j.bmc.2009.04.057. Epub 2009 May 3.

24.
25.

Pharmacy students' perceptions of a teaching evaluation process.

Surratt CK, Desselle SP.

Am J Pharm Educ. 2007 Feb 15;71(1):6.

26.
27.

Creation of a graduate oral/written communication skills course.

Surratt CK.

Am J Pharm Educ. 2006 Feb 15;70(1):5.

28.

Development of a neuroscience-oriented "methods" course for graduate students of pharmacology and toxicology.

Surratt CK, Witt-Enderby PA, Johnson DA, Anderson CA, Bricker JD, Davis VL, Firestine SM, Meng WS.

CBE Life Sci Educ. 2006 Summer;5(2):188-96.

30.
31.

G protein-coupled receptor structural motifs: relevance to the opioid receptors.

Surratt CK, Adams WR.

Curr Top Med Chem. 2005;5(3):315-24. Review.

PMID:
15857314
32.

Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.

Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, Surratt CK.

Mol Pharmacol. 2003 Aug;64(2):430-9.

PMID:
12869648
33.

beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.

Spivak CE, Beglan CL, Zöllner C, Surratt CK.

Synapse. 2003 Jul;49(1):55-60.

PMID:
12710015
34.

Control of mu opioid receptor expression by modification of cDNA 5'- and 3'-noncoding regions.

Zöllner C, Johnson PS, Bei Wang J, Roy AJ Jr, Layton KM, Min Wu J, Surratt CK.

Brain Res Mol Brain Res. 2000 Jun 23;79(1-2):159-62.

PMID:
10925154
36.

Role for the C-terminus in agonist-induced mu opioid receptor phosphorylation and desensitization.

Deng HB, Yu Y, Pak Y, O'Dowd BF, George SR, Surratt CK, Uhl GR, Wang JB.

Biochemistry. 2000 May 9;39(18):5492-9.

PMID:
10820022
37.

Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.

Zhang P, Johnson PS, Zöllner C, Wang W, Wang Z, Montes AE, Seidleck BK, Blaschak CJ, Surratt CK.

Brain Res Mol Brain Res. 1999 Oct 1;72(2):195-204.

PMID:
10529478
38.
39.

Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, Surratt CK.

Mol Pharmacol. 1997 Dec;52(6):983-92.

PMID:
9415708
40.

-mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.

Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, Uhl GR.

J Biol Chem. 1994 Aug 12;269(32):20548-53.

41.

Sodium- and chloride-dependent transporters in brain, kidney, and gut: lessons from complementary DNA cloning and structure-function studies.

Surratt CK, Wang JB, Yuhasz S, Amzel M, Kwon HM, Handler JS, Uhl GR.

Curr Opin Nephrol Hypertens. 1993 Sep;2(5):744-60. Review.

PMID:
7922216
42.

A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs.

Surratt CK, Persico AM, Yang XD, Edgar SR, Bird GS, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR.

FEBS Lett. 1993 Mar 8;318(3):325-30.

43.

Dopaminergic gene expression during amphetamine withdrawal.

Persico AM, Schindler CW, Brannock MT, Gonzalez AM, Surratt CK, Uhl GR.

Neuroreport. 1993 Jan;4(1):41-4.

PMID:
8095821
44.
45.

Metal ion and substrate structure dependence of the processing of tRNA precursors by RNase P and M1 RNA.

Surratt CK, Carter BJ, Payne RC, Hecht SM.

J Biol Chem. 1990 Dec 25;265(36):22513-9.

46.

Construction and processing of transfer RNA precursor models.

Surratt CK, Lesnikowski Z, Schifman AL, Schmidt FJ, Hecht SM.

J Biol Chem. 1990 Dec 25;265(36):22506-12.

47.

Preparation of misacylated aminoacyl-tRNA(Phe)'s useful as probes of the ribosomal acceptor site.

Roesser JR, Xu C, Payne RC, Surratt CK, Hecht SM.

Biochemistry. 1989 Jun 13;28(12):5185-95.

PMID:
2569893

Supplemental Content

Loading ...
Support Center